Revised SPCs: Keytruda (pembrolizumab) powder for concentrate for solution for infusion – all strengths

Source:
electronic Medicines Compendium - eMC
Publisher:
electronic Medicines compendium
Publication date:
25 November 2019

Abstract

The following new indication has been added: pembrolizumab, as monotherapy or in combination with platinum and 5-fluorouracil chemotherapy, for 1st line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma in adults.